XNNHQ Xenonics Holdings Inc (CE)

XENONICS HOLDINGS, INC. (OTCBB:XNNH) today announced financial results for fiscal 2013.

Revenue for the twelve months ended September 30, 2013 increased 10.1% to $2,383,000, compared to $2,164,000 for fiscal 2012. The net loss for fiscal 2013 was $1,542,000, or $0.06 per share. This compares to a net loss for fiscal 2012 of $2,189,000, or $0.09 per share.

Selling, general and administrative expenses decreased by 22.3% to $1,655,000 for fiscal 2013 from $2,130,000 for fiscal 2012.

At September 30, 2013, Xenonics reported total current assets of $1,431,000 and total current liabilities of $701,000.

The due dates for the principal balances for all of the Company's promissory notes payable were extended to October 15, 2014 from October 31, 2013 pursuant to an agreement between the Company and the holders of the promissory notes. On December 10, 2013, the Company borrowed $200,000 against new promissory notes due January 31, 2014. The holders of these notes have agreed to extend the due date for their loans to October 15, 2014 if the Company closes an additional $200,000 debt financing by January 31, 2014.

"These financial arrangements will enable Xenonics to pursue several opportunities for new orders for our NightHunter and SuperVision products in the coming months," said Chairman Alan Magerman.

Conference Call

Xenonics has scheduled a conference call at 11:00 a.m. EST this morning to discuss its results for the quarter. To participate in the call, dial (800) 901-5241, passcode #73410243. A simultaneous webcast of the conference call can be accessed from the Webcast Center of the Investor Relations link at www.xenonics.com. A replay will be available after 2:00 p.m. EST at this same Internet address. For a telephone replay, dial (888) 286-8010, passcode #97359507, after 2:00 p.m. EST.

About Xenonics

Xenonics Holdings, Inc. develops and produces advanced, lightweight and compact ultra-high-intensity illumination and low-light vision products for military, law enforcement, public safety, and commercial and private sector applications. Xenonics' NightHunter line of illumination products is used by every branch of the U.S. Armed Forces as well as law enforcement and security agencies. Its SuperVision high-definition night vision is designed for commercial and military applications. Employing patented technologies, Xenonics provides innovative solutions for customers who must see farther so they can do their jobs better and safer. Xenonics' products represent the next generation in small, high intensity, high efficiency illumination and low-light vision systems. Visit Xenonics on the web at www.xenonics.com.

Forward-Looking Statements

Except for the historical statements, statements in this release may constitute forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934. When used, the words "anticipates," "believes," "expects," "intends," "future," and other similar expressions identify forward-looking statements. These forward-looking statements reflect management's current views with respect to future events and financial performance and are subject to risks and uncertainties, and actual results may differ materially from the outcomes contained in any forward-looking statement. Factors that could cause these forward-looking statements to differ from actual results include delays in development, marketing or sales of new products, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. Xenonics Holdings undertakes no obligation to update or revise any forward-looking statements.

 

XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

   

Twelve months ended

 

September 30,

 

 

2013

 

 

 

2012

 

Rounded in thousands, except per share amounts

 

 

 

 

 

 

 

Revenue

$

2,383,000

 

$

2,164,000

 

 

 

 

Cost of goods sold

 

1,458,000

 

 

 

1,341,000

 

 

 

 

 

Gross profit

925,000

 

823,000

 

 

 

 

Selling, general and administrative

1,655,000

 

2,130,000

Research and development

 

343,000

 

 

 

720,000

 

 

 

 

 

Loss from operations

(1,073,000

)

 

(2,027,000

)

 

 

 

 

Other income (expense):

 

 

 

Other income

--

 

1,000

Interest income

--

 

1,000

Interest (expense)

 

(467,000

)

 

 

(162,000

)

 

 

 

 

Loss before provision for income taxes

 

(1,540,000

)

 

 

(2,187,000

)

 

 

 

 

Income tax provision

 

2,000

 

 

 

2,000

 

 

 

 

 

Net loss

$

(1,542,000

)

 

$

(2,189,000

)

 

 

 

 

Net loss per share:

 

 

 

Basic and diluted

$

(0.06

)

 

$

(0.09

)

 

 

 

 

Weighted average shares outstanding

 

 

 

Basic and diluted

 

24,976,000

 

 

 

24,976,000

     

XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   

 

 

 

 

September 30,

 

 

2013

 

 

 

2012

 

Rounded in thousands, except par value

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

220,000

 

$

367,000

Accounts receivable

30,000

 

58,000

Inventories

1,154,000

 

2,117,000

Other current assets

 

27,000

 

 

 

82,000

 

 

 

 

 

Total Current Assets

1,431,000

 

2,624,000

 

 

 

 

Inventories

480,000

 

--

Equipment, furniture and leasehold improvements at cost, net

11,000

 

14,000

Goodwill

375,000

 

375,000

Other assets

 

17,000

 

 

 

17,000

 

 

 

 

 

Total Assets

$

2,314,000

 

 

$

3,030,000

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders' Equity (Deficit)

 

 

 

 

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

399,000

 

$

281,000

Accrued expenses

211,000

 

134,000

Accrued payroll and related taxes

91,000

 

95,000

Notes payable

 

--

 

 

 

1,000,000

 

 

 

 

 

Total Current Liabilities

701,000

 

1,510,000

 

 

 

 

Notes payable, net of debt discount

 

1,962,000

 

 

 

525,000

 

 

 

 

 

Total Liabilities

 

2,663,000

 

 

 

2,035,000

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Shareholders' equity (deficit):

 

 

 

Preferred shares, $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding

--

 

--

Common shares, $0.001 par value, 50,000,000 shares authorized; 24,976,000 shares issued and outstanding at September 30, 2013 and September 30, 2012

25,000

 

25,000

Additional paid-in capital

26,879,000

 

26,681,000

Accumulated deficit

 

(27,253,000

)

 

 

(25,711,000

)

 

 

 

 

Total Shareholders' Equity (Deficit)

 

(349,000

)

 

 

995,000

 

 

 

 

 

Total Liabilities and Shareholders' Equity (Deficit)

$

2,314,000

 

 

$

3,030,000

 

Investor Contact:Berkman Associates(310) 477-3118info@BerkmanAssociates.comorCompany Contact:Xenonics Holdings, Inc.Alan Magerman, Chairman(760) 477-8900xenonics@xenonics.com